Trial Exclusions May Skew RA Drug Comparisons - Quiz - MDSpire

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.

  • By

  • Andrea Surnit

  • June 12, 2026

  • 5 min

Share

Original Source(s)

Trial Exclusions May Skew RA Drug Comparisons

  • by Andrea Surnit

  • June 12, 2026

Related Content

Lung Disease Complicates RA Care

Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Long-distance mentorship in rheumatology